Nucleic Acid Therapeutics

An Introduction
  • Alan M. Gewirtz
Chapter
Part of the Cancer Drug Discovery and Development book series (CDD&D)

Abstract

The development of simple, reliable tools for modifying gene expression “on demand” would represent a major technical advance for cell biologists. Because much progress has been made in understanding the molecular pathogenesis of many diseases, we may easily hypothesize that these same tools could be of tremendous importance to clinicians as well. For example, many genes responsible for cellular transformation have been identified. If the function of these genes were shown to be either completely or relatively tumor specific, they would become legitimate targets for therapeutic manipulation of their expression. More effective, less toxic cancer treatments could reasonably be expected to result if the strategy were successful.

Keywords

Human Immunodeficiency Virus Type Minor Groove Antisense Oligodeoxynucleotide Antisense Nucleic Acid Manipulate Gene Expression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Paterson BM, Roberts BE, Kuff EL. Structuralgene identification and mapping by DNA-mRNA hybrid-arrested cell-free translation. Proc Natl Acad Sci USA 1977; 74(10):4370–4374.PubMedCrossRefGoogle Scholar
  2. 2.
    Stephenson ML, Zamecnik PC. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci USA 1978; 75(1): 285–288.PubMedCrossRefGoogle Scholar
  3. 3.
    Simons RW, Kleckner N. Translational control of IS10 transposition. Cell 1983; 34(2): 683–691.PubMedCrossRefGoogle Scholar
  4. 4.
    Izant JG, Weintraub H. Inhibition of thymidine kinase gene expression by anti-sense RNA: a molecular approach to genetic analysis. Cell 1984; 36(4):1007–1015.PubMedCrossRefGoogle Scholar
  5. 5.
    Mizuno T, Chou MY, Inouye M. A unique mechanism regulating gene expression: translational inhibition by a complementary RNA transcript (micRNA). Proc Natl Acad Sci USA 1984; 81(7): 1966–1970.PubMedCrossRefGoogle Scholar
  6. 6.
    Gewirtz AM, Sokol DL, Ratajczak MZ. Nucleic acid therapeutics: state of the art and future prospects. Blood 1998; 92(3):712–736.PubMedGoogle Scholar
  7. 7.
    Opalinska JB, Gewirtz AM. Nucleic-acid therapeutics: basic principles and recent applications. Nat Rev Drug Discov 2002; 1(7):503–514.PubMedCrossRefGoogle Scholar
  8. 8.
    Melton DW. Gene targeting in the mouse. Bioessays 1994; 16(9):633–638.PubMedCrossRefGoogle Scholar
  9. 9.
    Stasiak A. Getting down to the core of homologous recombination [comment]. Science 1996; 272(5263):828–829.PubMedCrossRefGoogle Scholar
  10. 10.
    Helene C. Control of oncogene expression by antisense nucleic acids. Eur J Cancer 1994; 30A(11):1721–1726.PubMedCrossRefGoogle Scholar
  11. 11.
    Knauert MP, Glazer PM. Triplex forming oligonucleotides: sequence-specific tools for gene targeting. Hum Mol Genet 2001; 10(20):2243–2251.PubMedCrossRefGoogle Scholar
  12. 12.
    Sharma HW, Erez JR, Higgins-Sochaski K, Hsiao R, Narayanan R. Transcription factor decoy approach to decipher the role of NF-kappa B in oncogenesis. Anticancer Res 1996; 16(1):61–69.PubMedGoogle Scholar
  13. 13.
    Kielkopf CL, Baird EE, Dervan PB, Rees DC. Structural basis for G.0 recognition in the DNA minor groove. Nat Struct Biol 1998; 5(2):104–109.PubMedCrossRefGoogle Scholar
  14. 14.
    Kielkopf CL, White S, Szewczyk JW, et al. A structural basis for recognition of A.T and T.A base pairs in the minor groove of B-DNA. Science 1998; 282(5386):111–115.PubMedCrossRefGoogle Scholar
  15. 15.
    Kielkopf CL, Bremer RE, White S, et al. Structural effects of DNA sequence on T.A recognition by hydroxypyrrole/pyrrole pairs in the minor groove. J Mol Biol 2000; 295(3):557–567.PubMedCrossRefGoogle Scholar
  16. 16.
    Goodsell DS. The molecular perspective: DNA. Stem Cells 2000; 18(2):148–149.PubMedCrossRefGoogle Scholar
  17. 17.
    Urbach AR, Dervan PB. Toward rules for 1:1 polyamide:DNA recognition. Proc Natl Acad Sci USA 2001; 98(8):4343–4348.PubMedCrossRefGoogle Scholar
  18. 18.
    Beelman CA, Parker R. Degradation of mRNA in eukaryotes. Cell 1995; 81(2): 179–183.PubMedCrossRefGoogle Scholar
  19. 19.
    Liebhaber SA. mRNA stability and the control of gene expression. Nucleic Acids Symp Ser 1997; 36:29–32.PubMedGoogle Scholar
  20. 20.
    Baltimore D. Gene therapy. Intracellular immunization [news]. Nature 1988; 335(6189):395–396.PubMedCrossRefGoogle Scholar
  21. 21.
    Sullenger BA, Gallardo HF, Ungers GE, Gilboa E. Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation. J Virol 1991; 65(12):6811–6816.PubMedGoogle Scholar
  22. 22.
    Bevec D, Volc-Platzer B, Zimmermann K, et al.. Constitutive expression of chimeric neo-Rev response element transcripts suppresses HIV-1 replication in human CD4+ T lymphocytes. Hum Gene Ther 1994; 5(2):193–201.PubMedCrossRefGoogle Scholar
  23. 23.
    Weiss IM, Liebhaber, SA. Erythroid cell-specific mRNA stability elements in the alpha 2globin 3’ nontranslated region. Mol Cell Biol 1995; 15(5):2457–2465.PubMedGoogle Scholar
  24. 24.
    Wang X, Kiledjian M, Weiss IM, Liebhaber SA. Detection and characterization of a 3’ untranslated region ribonucleoprotein complex associated with human alpha-globin mRNA stability [published erratum appears in Mol Cell Biol 1995 Apr;15(4):2331]. Mol Cell Biol 1995; 15(3):1769–1777.PubMedGoogle Scholar
  25. 25.
    Thisted T, Lyakhov DL, Liebhaber SA. Optimized RNA targets of two closely related triple KH domain proteins, heterogeneous nuclear ribonucleoprotein K and alphaCP-2KL, suggest distinct modes of RNA recognition. PG-17484–96. J Biol Chem 2001; 276(20):17484–17496.PubMedCrossRefGoogle Scholar
  26. 26.
    Scanlon KJ, Ohta Y, Ishida H, et al. Oligonucleotide-mediated modulation of mammalian gene expression. Faseb J 1995; 9(13):1288–1296.PubMedGoogle Scholar
  27. 27.
    Stein CA. How to design an antisense oligodeoxynucleotide experiment: a consensus approach. Antisense Nucleic Acid Drug Dev 1998; 8(2):129–132.PubMedCrossRefGoogle Scholar
  28. 28.
    Nishikura K. A Short primer on RNAi: RNA-directed RNA polymerase acts as a key catalyst. Cell 2001; 107(4): 415–418.PubMedCrossRefGoogle Scholar
  29. 29.
    Sharp PA. RNAi and double-strand RNA. Genes Dev 1999; 13(2):139–141.PubMedCrossRefGoogle Scholar
  30. 30.
    Hutvagner G, McLachlan J, Pasquinelli AE, Balint E, Tuschl T, Zamore PD. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science 2001; 293(5531):834–838.PubMedCrossRefGoogle Scholar
  31. 31.
    Ketting RF, et al. Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans. Genes Dev 2001; 15(20):2654–2659.PubMedCrossRefGoogle Scholar
  32. 32.
    Nicholson RH, Nicholson AW. Molecular characterization of a mouse cDNA encoding Dicer, a ribonuclease III ortholog involved in RNA interference. Mamm Genome 2002; 13(2):67–73.PubMedCrossRefGoogle Scholar
  33. 33.
    Hammond SM, Boetther S, Caudy AA, Kobaashi R, Hannon GJ. Argonaute2, a link between genetic and biochemical analyses of RNAi. Science 2001; 293(5532):1146–1150.PubMedCrossRefGoogle Scholar
  34. 34.
    Williams RW, Rubin GM. ARGONAUTE1 is required for efficient RNA interference in Drosophila embryos. Proc Natl Acad Sci USA 2002; 99(10):6889–6894.PubMedCrossRefGoogle Scholar
  35. 35.
    Martinez J, Patkaniowska A, Urlaub H, Luhrmann R, Tuschl T. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 2002; 110(5):563–574.PubMedCrossRefGoogle Scholar
  36. 36.
    Yang S, Tutton S, Pierce E, Yoon K. Specific double-stranded RNA interference in undifferentiated mouse embryonic stem cells. Mol Cell Biol 2001; 21(22):7807–7816.PubMedCrossRefGoogle Scholar
  37. 37.
    Bernstein E, Denli AM, Hannon GJ. The rest is silence. RNA, 2001; 7(11):1509–1521.PubMedGoogle Scholar
  38. 38.
    Yang D, Lu H, Erickson JW. Evidence that processed small dsRNAs may mediate sequencespecific mRNA degradation during RNAi in Drosophila embryos. Curr Biol 2000; 10(19):1191–200.PubMedCrossRefGoogle Scholar
  39. 39.
    Zamore PD, Tuschl T, Sharp PA, Bartel DP. RNAi: double-stranded RNA directs the ATPdependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 2000; 101(1):25–33.PubMedCrossRefGoogle Scholar
  40. 40.
    Elbashir SM, Martinez J, Patkaniowska A, Lndeckel W, Tuschl T. Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. Embo J 2001; 20(23):6877–6888.PubMedCrossRefGoogle Scholar
  41. 41.
    Hannon GJ. RNA interference. Nature 2002; 418(6894):244–251.PubMedCrossRefGoogle Scholar
  42. 42.
    Yu JY, DeRuiter SL, Turner DL. RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proc Natl Acad Sci USA 2002; 99(9):6047–6052.PubMedCrossRefGoogle Scholar
  43. 43.
    Donze O, Picard DL. RNA interference in mammalian cells using siRNAs synthesized with T7 RNA polymerase. Nucleic Acids Res 2002; 30(10):e46.PubMedCrossRefGoogle Scholar
  44. 44.
    Sui G, Soohoo C, Affar el B, Gay F, et al. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci USA 2002; 99(8):5515–5520.PubMedCrossRefGoogle Scholar
  45. 45.
    Paddison PJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev 2002; 16(8):948–958.PubMedCrossRefGoogle Scholar
  46. 46.
    Lassus P, Rodriguez J, Lazebnik Y. Confirming Specificity of RNAi in mammalian cells. Sci STKE 2002; 147:PL13.Google Scholar
  47. 47.
    Holen T, Amarzguioui M, Wiiger MT, Babaie E, Prydz H. Positional effects of short interfering RNAs targeting the human coagulation trigger tissue factor. Nucleic Acids Res 2002; 30(8):1757–1766.PubMedCrossRefGoogle Scholar
  48. 48.
    Luger SM, O’Brien SG, Ratajczak J, et al. Oligodeoxynucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow: a pilot study. Blood 2002; 99(4):1150–1158.PubMedCrossRefGoogle Scholar
  49. 49.
    Methia N, Louache F, Vainchenker W, Wendling F. Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis. Blood 1993; 82(5):1395–13401.PubMedGoogle Scholar
  50. 50.
    Webb A, Cunningham D, Cotter F, et al. BCL-2 antisense therapy in patients with nonHodgkin lymphoma. Lancet 1997; 349(9059):1137–1141.PubMedCrossRefGoogle Scholar
  51. 51.
    Gewirtz AM, Stein CA, Glazer PM. Facilitating oligonucleotide delivery: helping antisense deliver on its promise. Proc Natl Acad Sci USA 1996; 93(8):3161–3163.PubMedCrossRefGoogle Scholar
  52. 52.
    Stein CA, Does antisense exist? Nat Med 1995; 1(11):1119–1121.PubMedCrossRefGoogle Scholar
  53. 53.
    Wagner RW, Flanagan WM. Antisense technology and prospects for therapy of viral infections and cancer. Mol Med Today 1997; 3(1):31–38.PubMedCrossRefGoogle Scholar
  54. 54.
    Baskerville S, Ellington AD. RNA structure. Describing the elephant. Curr Biol 1995; 5(2):120–123.PubMedCrossRefGoogle Scholar
  55. 55.
    Sokol DL, Zhang X, Lu P. Gewirtz AM. Real time detection of DNA. RNA hybridization in living cells. Proc Natl Acad Sci USA, 1998; 95(20):11538–11543.PubMedCrossRefGoogle Scholar
  56. 56.
    Yakubov LA, Deeva EA, Zarytova VF, et al. Mechanism of oligonucleotide uptake by cells: involvement of specific receptors? Proc Natl Acad Sci USA 1989; 86(17):6454–6458.PubMedCrossRefGoogle Scholar
  57. 57.
    Beltinger C, et al. Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J Clin Invest 1995; 95(4):1814–1823.PubMedCrossRefGoogle Scholar
  58. 58.
    Arima H, Aramaki Y, Tsuchiya S. Effects of oligodeoxynucleotides on the physicochemical characteristics and cellular uptake of liposomes. J Pharm Sci 1997; 86(4): 438–442.PubMedCrossRefGoogle Scholar
  59. 59.
    Laktionov PP, Dazard JE, Vives E, et al. Characterisation of membrane oligonucleotidebinding proteins and oligonucleotide uptake in keratinocytes. Nucleic Acids Res 1999; 27(11):2315–2324.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2004

Authors and Affiliations

  • Alan M. Gewirtz

There are no affiliations available

Personalised recommendations